Defence Therapeutics’ (DTC) is pleased to announce strong in vitro results of its AccumTM variants on the recent Enhertu®ADC owned by AstraZeneca and Daiichi Sankyo.
Defence has selected and tested 5 Accum variants to the T-deruxtecan ADC Therapeutic. The 5 selected Accum-T-deruxtecan increases the potency of T-deruxtecan ADC Therapeutic by approximately 5-fold on the HER2 positive breast cancer Trastuzumab and T-DM1 resistant cell line model named JIMT-1.
The 5 selected Accum variants will be sent to our collaborator at the HUS Comprehensive Cancer Center in Helsinki for the optimization of Defence’s Accum-T-deruxtecan ADC Therapeutic.
Defence’s Accum platform has been developed and tested in vitro to enhance the intracellular drug delivery on multiple ADCs that are FDA approved or under development.
The Accum technology platform is very efficient at enhancing intracellular delivery of proteins of pharmacological interests such as ADCs or vaccine antigens.
Mr. Sebastien Plouffe, CEO of Defence Therapeutics commented on the results.
“The strong results confirmed the expectation of our scientific team that the Accum can increase the routing and delivery of the T-deruxtecan to the nucleus and consequently increased more significantly the potency of the ADC. That confirms also and again the strength and optimization of our Accum platform in the ADC field of therapeutics against cancer and the solid competitive advantage we have with our Accum technology platform.”
Defence Therapeutics is a biotechnology company focused on engineering the next-generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.
Defence Therapeutics Inc. (DTC) opened trading at C$6.60 per share.